Vigil Neuroscience, Inc. - VIGL STOCK NEWS

Vigil Neuroscience, a clinical-stage biotechnology firm (Nasdaq: VIGL), announced its participation in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022, at 11:30 a.m. ET. The management team will engage in a fireside chat to discuss the company’s focus on microglia-targeted therapies for neurodegenerative diseases. Investors can access the live webcast through the ‘Events & Presentations’ section of Vigil's website, with an archived replay available for 90 days after the event.

The company aims to restore microglial function to develop precision-based treatments.

Vigil Neuroscience (Nasdaq: VIGL) recently presented findings at the Alzheimer's Association International Conference. Their lead product candidate, VGL101, showed promise in treating Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP). The study revealed VGL101's ability to rescue microglial dysfunction in preclinical models. A systematic review indicated a mean age of onset for ALSP symptoms at 43.2 years. The company emphasizes the importance of genetic testing due to frequent misdiagnoses as other neurodegenerative diseases.

Vigil Neuroscience (Nasdaq: VIGL) has appointed Suzanne Bruhn, Ph.D., to its Board of Directors, enhancing its leadership with over 20 years of biopharmaceutical experience. Dr. Bruhn's expertise in rare diseases and neuroscience is seen as an asset for Vigil’s mission to develop microglia-targeted therapies for neurodegenerative conditions. Notably, she has held significant roles in successful organizations, including Tiaki Therapeutics and Proclara Biosciences. This leadership change is expected to bolster Vigil's strategic direction in drug development, although it also introduces potential risks associated with transitioning leadership.

Vigil Neuroscience has received approval from the Human Research Ethics Committee in Australia to conduct a Phase 1 trial of VGL101 in healthy volunteers, allowing doses above 20 mg/kg. The FDA has also suggested considering a 30 mg/kg dose for the U.S. trial. Vigil is on track to report topline data from this trial and initiate a Phase 2 trial for ALSP in Q4 2022. The company emphasizes the favorable safety and pharmacokinetic profile of VGL101, aimed at treating neurodegenerative diseases, specifically ALSP.

Vigil Neuroscience, Inc. (Nasdaq: VIGL) has announced that CEO Ivana Magovčević-Liebisch, Ph.D., J.D., will speak at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 2:00 p.m. ET in New York City. The event will focus on the company's commitment to leveraging microglia to develop therapies for neurodegenerative diseases. A live webcast of the discussion can be accessed through the 'Investors' section of their website, with an archived replay available for 90 days post-event.

Vigil Neuroscience (Nasdaq: VIGL) announced its Q1 2022 financial results, revealing cash and equivalents at $163.3 million, up from $91.4 million in Q4 2021. Research and development expenses rose to $10.4 million from $6.8 million year-over-year, while general and administrative expenses increased to $5.0 million from $1.2 million. The net loss for the quarter was $15.3 million compared to $8.2 million in the same period last year. Vigil continues to advance its VGL101 trial for ALSP and aims to initiate a Phase 1b trial for Alzheimer's disease in late 2022.

Vigil Neuroscience announced the appointment of Christopher Verni as General Counsel and Mary Thistle to its Board of Directors on April 20, 2022. This strategic move is aimed at strengthening the company's leadership during a critical growth phase. Verni brings over 20 years of legal experience in biopharma, previously serving in key roles at Sarepta Therapeutics and ARIAD Pharmaceuticals. Thistle, with over 25 years in biopharmaceutical strategy and financing, has a record of successfully developing and expanding product pipelines. Their expertise is expected to enhance Vigil's efforts in developing innovative therapeutics.

Vigil Neuroscience, Inc. (Nasdaq: VIGL) recently completed a successful IPO, raising $98 million in gross proceeds. In 2021, the company initiated its VGL101 Phase 1 trial and plans to start a Phase 2 trial in ALSP patients in the second half of 2022. Vigil also initiated IND-enabling studies for a small molecule Alzheimer’s disease program. Financially, Vigil reported a net loss of $43.3 million for 2021, up from $28.5 million in 2020, driven by increased R&D expenses. Despite this, the company has cash reserves expected to fund operations into 2024.

Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on neurodegenerative diseases, announced participation in the Stifel 2022 CNS Days conference. CEO Ivana Magovčević-Liebisch, Ph.D., J.D., will join a fireside chat on March 28, 2022, at 9:45 a.m. ET. This event can be accessed via a live webcast on the Vigil website. The company aims to create precision-based therapies by leveraging microglia, the brain's immune cells, for treating various neurodegenerative conditions.